Cajal Therapeutics Company Profile - aVenture Research
Cajal Therapeutics
Cajal Therapeutics is a Seattle biotechnology company developing iron-mobilizing medicines for anemias of inflammation, neurodegenerative disease, and other iron-related disorders.
Cajal Therapeutics is a Seattle biotechnology company developing novel medicines for serious diseases involving iron regulation, including anemias of inflammation, neurodegenerative diseases, and other iron-related disorders. The company raised a $96 million Series A financing led by The Column Group and Lux Capital with participation from Two Sigma Ventures, Bristol Myers Squibb, Evotec, Alexandria Venture Investments, and Dolby Family Ventures.
Its lead program is CTX001, a first-in-class iron mobilizer advancing through a pipeline of iron-homeostasis therapies. Led by co-CEOs Andrew Dervan and Ian Peikon with executive chairman Rob Hershberg, the company operates from 1150 Eastlake Avenue E in Seattle.